Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26032
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCutler, Cathy S-
dc.contributor.authorBailey, Elizabeth-
dc.contributor.authorKumar, Vijay-
dc.contributor.authorSchwarz, Sally W-
dc.contributor.authorBom, Hee-Seung-
dc.contributor.authorHatazawa, Jun-
dc.contributor.authorPaez, Diana-
dc.contributor.authorOrellana, Pilar-
dc.contributor.authorLouw, Lizette-
dc.contributor.authorMut, Fernando-
dc.contributor.authorKato, Hiroki-
dc.contributor.authorChiti, Arturo-
dc.contributor.authorFrangos, Savvas-
dc.contributor.authorFahey, Frederic-
dc.contributor.authorDillehay, Gary-
dc.contributor.authorOh, Seung J-
dc.contributor.authorLee, Dong S-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorNunez-Miller, Rodolfo-
dc.contributor.authorBandhopadhyaya, Guru-
dc.contributor.authorPradhan, Prasanta K-
dc.contributor.authorScott, Andrew M-
dc.date2020-07-09-
dc.date.accessioned2021-03-09T05:05:17Z-
dc.date.available2021-03-09T05:05:17Z-
dc.date.issued2021-03-
dc.identifier.citationJournal of Nuclear Medicine 2021; 62(3): 422-430en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26032-
dc.description.abstractThe Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the practice and application of nuclear medicine. The first project focused on standardization of administered activities in pediatric nuclear medicine and resulted in 2 articles. For its second project the Nuclear Medicine Global Initiative chose to explore issues impacting on access and availability of radiopharmaceuticals around the world. Methods: Information was obtained by survey responses from 35 countries on available radioisotopes, radiopharmaceuticals, and kits for diagnostic and therapeutic use. Issues impacting on access and availability of radiopharmaceuticals in individual countries were also identified. Results: Detailed information on radiopharmaceuticals used in each country, and sources of supply, was evaluated. Responses highlighted problems in access, particularly due to the reliance on a sole provider, regulatory issues, and reimbursement, as well as issues of facilities and workforce, particularly in low- and middle-income countries. Conclusion: Strategies to address access and availability of radiopharmaceuticals are outlined, to enable timely and equitable patient access to nuclear medicine procedures worldwide. In the face of disruptions to global supply chains by the coronavirus disease 2019 outbreak, renewed focus on ensuring a reliable supply of radiopharmaceuticals is a major priority for nuclear medicine practice globally.en
dc.language.isoeng
dc.subjectaccessen
dc.subjectglobal issuesen
dc.subjectradiopharmaceuticalsen
dc.titleGlobal Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Nuclear Medicineen
dc.identifier.affiliationBrookhaven National Laboratory, Upton, New Yorken
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health; University of Melbourne; Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australiaen
dc.identifier.affiliationDepartment of Biomedical Sciences, Humanitas University, and Nuclear Medicine Unit, Humanitas Research Hospital-IRCCS, Milan, Italyen
dc.identifier.affiliationUniversity of Melbourneen
dc.identifier.affiliationExcel Diagnostics and Nuclear Oncology Center, Houston, Texasen
dc.identifier.affiliationNuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austriaen
dc.identifier.affiliationDepartment of Nuclear Medicine and PET, Westmead Hospital and Children's Hospital at Westmead, and University of Sydney, New South Wales, Australiaen
dc.identifier.affiliationWashington University School of Medicine, St Louis, Missourien
dc.identifier.affiliationDepartment of Nuclear Medicine, Chonnam National University Hwasun Hospital, Jeollanam, Koreaen
dc.identifier.affiliationDepartment of Quantum Cancer Therapy, Research Center for Nuclear Physics, Osaka University, Osaka, Japanen
dc.identifier.affiliationNuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austriaen
dc.identifier.affiliationDepartment of Nuclear Medicine, Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand, Johannesburg, South Africaen
dc.identifier.affiliationNuclear Medicine Service, Italian Hospital, Montevideo, Uruguayen
dc.identifier.affiliationDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japanen
dc.identifier.affiliationDepartment of Nuclear Medicine, Bank of Cyprus Oncology Center, Nicosia, Cyprusen
dc.identifier.affiliationDepartment of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusettsen
dc.identifier.affiliationDepartment of Radiology, Division of Nuclear Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinoisen
dc.identifier.affiliationDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Koreaen
dc.identifier.affiliationDepartment of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Koreaen
dc.identifier.affiliationDepartment of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Indiaen
dc.identifier.affiliationDepartment of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Nuclear Medicine, Lucknow, Indiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.doi10.2967/jnumed.120.247197en
dc.type.contentTexten
dc.identifier.pubmedid32646881
local.name.researcherLee, Sze Ting
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Nov 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.